American Portfolios Advisors Oncocyte Corp Transaction History

American Portfolios Advisors

$2.36 Trillion
Q3 2022

A detailed history of American Portfolios Advisors transactions in Oncocyte Corp stock. As of the latest transaction made, American Portfolios Advisors holds 21,830 shares of OCX stock, worth $64,398. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,830

Holding current value

$64,398

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Mar 17, 2023	BUY	$0.76 - $0.99 $16,590 - $21,611	21,830 New	21,830 $15.9 Million
Q1 2022 Mar 21, 2023	SELL	$1.15 - $2.25 $11,500 - $22,500	-10,000 Reduced 45.81%	11,830 $17.6 Million
Q4 2021 Mar 21, 2023	SELL	$2.04 - $3.59 $19,176 - $33,746	-9,400 Reduced 43.06%	12,430 $27 Million
Q3 2021 Mar 22, 2023	SELL	$3.53 - $5.89 $33,005 - $55,071	-9,350 Reduced 42.83%	12,480 $44.4 Million
Q2 2021 Mar 22, 2023	SELL	$3.77 - $6.0 $35,249 - $56,100	-9,350 Reduced 42.83%	12,480 $71.6 Million

Q1 2021 Mar 22, 2023	SELL	$2.39 - $6.5 $22,346 - $60,775	-9,350 Reduced 42.83%	12,480 $64.8 Million
Q4 2020 Mar 22, 2023	SELL	$1.38 - $2.63 $29,297 - $55,834	-21,230 Reduced 97.25%	600 $1.43 Million
Q3 2020 Mar 22, 2023	SELL	$1.2 - $1.89 $25,410 - $40,020	-21,175 Reduced 97.0%	655 $910,000
Q1 2020 Mar 24, 2023	SELL	$1.76 - $3.02 $33,396 - $57,304	-18,975 Reduced 86.92%	2,855 $7 Million
Q4 2019 Mar 24, 2023	SELL	$1.51 - $2.27 $30,917 - $46,478	-20,475 Reduced 93.79%	1,355 $3.05 Million
Q3 2019 Mar 24, 2023	SELL	$1.59 - $2.51 $32,555 - $51,392	-20,475 Reduced 93.79%	1,355 $2.85 Million

Others Institutions Holding OCX

# of Institutions

Shares Held

1.16M

Call Options Held

Put Options Held

View Full List

About Oncocyte Corp

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $350M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

More about OCX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Account

American Portfolios Advisors Oncocyte Corp Transaction History